Stock Forecast

  Checkmate Pharmaceuticals, Inc. ( CMPI) Stock. Should you Buy or Sell?    $ 10.50

0.00 (0.00 %)



Checkmate Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol CMPI
Price $10.50
Beta 0.000
Volume Avg. $233.02 thousand
Market Cap $227.12 M
52 Week Range $2.0 - $10.5


Checkmate Pharmaceuticals, Inc. opened the day at $10.50 which is 0.00 % on yesterday's close. Checkmate Pharmaceuticals, Inc. has a 52 week high of $10.5 and 52 week low of $2.0, which is a difference of $8.5. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $227.12 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Checkmate Pharmaceuticals, Inc. for $227.12 M, it would take 15 years to get your money back. Checkmate Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Checkmate Pharmaceuticals, Inc. Stock Forecast - Is Checkmate Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -3.597
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Checkmate Pharmaceuticals, Inc.


Price Book Value Ratio 4.129 Price To Book Ratio 4.129
Price To Sales Ratio 0.000 Price Earnings Ratio -3.597


How liquid is Checkmate Pharmaceuticals, Inc.


Current Ratio 5.201
Quick Ratio 5.027


Debt


Debt Ratio 0.178 Debt Equity Ratio 0.217
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Checkmate Pharmaceuticals, Inc.


Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today

Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.

Date : 19/04/2022

Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?

Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?

Date : 19/04/2022

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the company for $10.50 per share in cash. Checkmate's lead investigational candidate.

Date : 19/04/2022

Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.

Date : 19/04/2022

Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Date : 19/04/2022





About Checkmate Pharmaceuticals, Inc.


CEO : Mr. Barry A. Labinger
Sector : Healthcare
Industry : Biotechnology

Website : https://www.checkmatepharma.com

Exchange : NASDAQ Global Market

Description :

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.


My Newsletter

Sign Up For Updates & Newsletters